NCT06874010View on ClinicalTrials.gov

A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

March 31, 2027

Conditions
Friedreich Ataxia
Interventions
DRUG

DT-216P2

Active

Trial Locations (3)

2031

RECRUITING

Scientia Clinical Research Ltd, Sydney

3002

RECRUITING

Doherty Clinical Trials, East Melbourne

3004

RECRUITING

Nucleus Network, Melbourne

Sponsors
All Listed Sponsors
lead

Design Therapeutics, Inc.

INDUSTRY

NCT06874010 - A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia | Biotech Hunter | Biotech Hunter